Summary:
In women with type 2 diabetes, sitagliptin treatment significantly preserved total hip bone mineral density (T score) compared to placebo, though it was associated with no consistent effects on other bone sites or bone turnover markers.
| PICO | Description |
|---|---|
| Population | Women diagnosed with type 2 diabetes mellitus. |
| Intervention | Sitagliptin administered at standard therapeutic dosing over the study period. |
| Comparison | Placebo treatment administered under identical conditions. |
| Outcome | Sitagliptin preserved total hip T score compared to placebo, indicating beneficial effects on bone mineral density at this site. No consistent changes were observed in other skeletal sites or bone turnover biomarkers. Findings suggest potential added benefit of sitagliptin beyond glycemic control. |
Source: Barchetta, Ilaria, et al. “Effect of sitagliptin vs. placebo on bone mineralization in women with type 2 diabetes: the SLowDOWN (SitagLiptin in Diabetes for Osteoporosis in WomeN) randomized clinical trial.” Read article here.
